Hyloris Pharmaceuticals S.A.
HYL.BR · BRU
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | €0 | €0 | €0 | €0 |
| - Cash | €0 | €0 | €0 | €0 |
| + Debt | €0 | €0 | €0 | €0 |
| Enterprise Value | €0 | €0 | €0 | €0 |
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | 0% | -38.2% | 0% | – |
| Gross Profit | €0 | €0 | €0 | €0 |
| % Margin | 96.2% | 96.2% | 97.8% | 97.8% |
| EBITDA | -€0 | -€0 | -€0 | -€0 |
| % Margin | -96.4% | -96.4% | -22.6% | -22.6% |
| Net Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | -106.5% | -106.5% | -52.9% | -52.9% |
| EPS Diluted | -0.065 | -0.065 | -0.049 | -0.049 |
| % Growth | 0% | -32.7% | 0% | – |
| Operating Cash Flow | -€0 | -€0 | -€0 | -€0 |
| Capital Expenditures | €0 | €0 | -€0 | -€0 |
| Free Cash Flow | -€0 | -€0 | -€0 | -€0 |